Overview of the Announcement - The announcement details the freezing of bank accounts of the wholly-owned subsidiary Shanghai Gengxing Energy Co., Ltd. due to a property preservation application filed by former executives over labor contract disputes [1][3]. Summary of Frozen Accounts - The total amount applied for freezing across various accounts is 2,645,824.44 yuan, with an actual frozen amount of 10,995.13 yuan for the newly frozen accounts [1][2]. - Cumulatively, the actual frozen amount for all accounts is 1,613,937.57 yuan, which represents 5.5702% of the company's latest audited cash funds [3]. Reasons for Account Freezing - The freezing of accounts is attributed to disputes involving former director and general manager Tang Yonglu and former vice general manager and financial officer Liang Mingmei [1][3]. Company's Response and Measures - The company plans to handle the disputes legally and aims to restore the normal status of the frozen accounts promptly [1][3]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required by law [4].

Core Viewpoint - The company, Tongde Chemical, is facing financial pressure due to the freezing of several bank accounts related to a contract dispute with Qingdao Huaton Financing Leasing Co., which may impact its liquidity and future financing options [2][3][4]. Group 1: Account Freezing Incident - On July 21, Tongde Chemical announced that four bank accounts were frozen by the Qingdao Shila District People's Court, involving a total amount of 87 million yuan [3]. - The frozen accounts included the company's basic accounts at China Construction Bank and Bank of China, with a total balance of 10.91 million yuan, representing 0.55% of the company's latest audited net assets and 5.82% of its cash balance [3]. - This is the second account freezing incident for the company, following a similar event in May involving 32.24 million yuan due to a dispute with Far East International Financing Leasing Co. [4]. Group 2: Financial Performance - Tongde Chemical reported a significant increase in net profit for 2023, reaching 438 million yuan, a 138.10% increase year-on-year, primarily due to gains from the sale of subsidiaries [6]. - However, the company experienced a sharp decline in performance in 2024, with total revenue dropping to 54.5 million yuan, a 43.52% decrease from 2023, and a net loss of 71.99 million yuan [6]. - For the first half of 2025, the company expects a net profit of 6.5 to 9.5 million yuan, representing a year-on-year decline of 79.24% to 85.79%, attributed to reduced demand for explosives and losses in its electricity business [7].

Core Viewpoint - The article discusses the ongoing regulatory issues faced by *ST Suwu, including the investigation of its chairman by the China Securities Regulatory Commission (CSRC) and the implications for the company's financial health and operations [2][3]. Group 1: Regulatory Issues - The chairman of *ST Suwu, Qian Qunshan, is under investigation by the CSRC, which has issued a notice of investigation. This investigation is focused solely on the chairman and is not expected to significantly impact the company's daily operations [3]. - In February 2024, *ST Suwu received a notice from the CSRC regarding suspected violations of information disclosure laws, which could lead to severe penalties, including potential delisting [3][8]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year, and a net profit attributable to shareholders of 70.48 million yuan [6]. - The company has been issued a non-standard audit opinion due to issues related to the misuse of funds by related parties, with 769 million yuan reported as misappropriated and not returned [6]. Group 3: Business Operations - *ST Suwu operates in the pharmaceutical sector through its subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [4]. - The company aims to develop a dual-driven strategy focusing on both pharmaceutical and medical beauty sectors, leveraging opportunities in the health industry to enhance market competitiveness [6]. Group 4: Legal and Financial Risks - The company faces additional legal challenges, including a lawsuit against its subsidiary's former legal representative for alleged fraud related to export tax rebates, with the first court hearing scheduled for April 2025 [7]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [7].

Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].

Core Viewpoint - The company, Jiangsu Wuzhong Pharmaceutical Development Co., Ltd., is facing significant risks due to an investigation by the China Securities Regulatory Commission (CSRC) and the freezing of several bank accounts due to overdue loans, which may impact its financing capabilities and operations [2][4]. Group 1: Bank Account Freezing - The company and its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Sales Co., Ltd., have had a total of 31 bank accounts frozen, with a total amount of approximately RMB 2.65 million, accounting for 0.15% of the company's latest audited net assets [2][3]. - The freezing of accounts is primarily due to a financial loan dispute with Nanyang Commercial Bank (China) Co., Ltd., Suzhou Branch, where the subsidiary has an overdue loan of RMB 20.96 million [3][4]. Group 2: Impact on Operations - Currently, the company's production and operations are proceeding normally, and the freezing of bank accounts has not significantly affected its cash flow or operational activities [4]. - However, the ongoing investigation by the CSRC and the overdue debts may lead to a decline in the company's financing capabilities, potentially impacting some business operations [4]. Group 3: Response Measures - The company is actively communicating with relevant parties to resolve the issues related to the frozen accounts and is seeking new financing channels and optimizing its debt structure to mitigate debt risks [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301152 证券简称：天力锂能 公告编号：2025-021 天力锂能集团股份有限公司 关于公司银行账户新增资金冻结事项的公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公告中的虚假记载、误导性陈 述或者重大遗漏承担责任。 天力锂能集团股份有限公司（以下简称"公司"或"天力锂能"）于近日获悉东莞市第二人民法院冻结公司 及全资子公司四川天力锂能有限公司（以下简称"四川天力"）部分银行账户，现将有关情况公告如下： 一、银行账户被冻结的基本情况 1、被冻结银行账户基本情况 ■ 截至本公告日，公司尚未收到法院送达的正式法律文书，公司正积极跟进、核查本事项，后续将及时履 行信息披露义务。 二、公司的后续解决措施 公司已委托律师向法院提起诉讼，案件已进入审理程序。公司将积极推进相关法律程序，依法维护自身 合法权益，并争取尽快解除银行账户冻结。 三、对公司的影响 截至本公告日，公司及全资子公司银行账户合计被冻结资金人民币 9,119,903.81元，占公司最近一期经 审计净资产的0.46%，占期末货币资金余额的3.30%。根据公司最近一期经审 ...